var data={"title":"Decitabine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Decitabine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/224555?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=decitabine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Decitabine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520518\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dacogen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930138\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimetabolite;</li>\n      <li>\n        Antineoplastic Agent, DNA Methylation Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930507\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Myelodysplastic syndromes (MDS):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/m<sup>2</sup> over 3 hours every 8 hours (45 mg/m<sup>2</sup>/day) for 3 days (135 mg/m<sup>2</sup>/cycle) every 6 weeks; treatment is recommended for at least 4 cycles and may continue until the patient no longer benefits.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adjustment for prolonged hematologic toxicity (ANC &lt;1,000/mm<sup>3</sup> and platelets &lt;50,000/mm<sup>3</sup>):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;6 weeks but &lt;8 weeks: Delay dose for up to 2 weeks and temporarily reduce dose to 11 mg/m<sup>2</sup> every 8 hours (33 mg/m<sup>2</sup>/day) for 3 days (99 mg/m<sup>2</sup>/cycle)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;8 weeks but &lt;10 weeks: Assess for disease progression; if no disease progression, delay dose for up to 2 weeks and reduce dose to 11 mg/m<sup>2</sup> every 8 hours (33 mg/m<sup>2</sup>/day) for 3 days (99 mg/m<sup>2</sup>/cycle); maintain or increase dose with subsequent cycles if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/m<sup>2</sup> over 1 hour daily for 5 days every 28 days (delay subsequent treatment cycles until hematologic recovery [ANC &ge;1,000/mm<sup>3</sup> and platelets &ge;50,000/mm<sup>3</sup>]); treatment is recommended for at least 4 cycles and may continue until the patient no longer benefits.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Acute myeloid leukemia (AML) (off-label use):</b> Adults &ge;60 years: IV: 20 mg/m<sup>2</sup> over 1 hour daily for 5 days every 28 days until relapse, disease progression, or unacceptable toxicity (Cashen 2010; Kantarjian 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930508\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15796000\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Preexisting impairment: </i>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Renal toxicity during treatment:</i> Serum creatinine &ge;2 mg/dL: Temporarily hold treatment until resolution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15796001\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Preexisting impairment: </i>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatotoxicity during treatment:</i> ALT and/or bilirubin &ge;2 times ULN: Temporarily hold treatment until resolution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930511\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Hematologic toxicity (ANC &lt;1,000/mm<sup>3</sup> and platelets &lt;50,000/mm<sup>3</sup>): Delay and/or reduce dose; refer to adult dosing for  recommendations specific to each MDS dosing regimen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nonhematologic toxicity: Temporarily hold treatment until resolution for any of the following toxicities: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serum creatinine &ge;2 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ALT, bilirubin &ge;2 times ULN</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Active or uncontrolled infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930518\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dacogen: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930136\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930512\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 1 to 3 hours. For the treatment of myelodysplastic syndromes, administer by IV infusion over 3 hours (15 mg/m<sup>2</sup> dose) or over 1 hour (20 mg/m<sup>2</sup> dose). For the treatment of acute myeloid leukemia (off-label use), administer by IV infusion over 1 hour (Cashen 2010; Kantarjian 2012). Premedication with antiemetics is recommended according to the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130971\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930140\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Myelodysplastic syndromes:</b> Treatment of myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725528\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute myeloid leukemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401603\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dacogen may be confused with azaCITIDine, DACTINomycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930489\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (25% to 27%), edema (5% to 18%), heart murmur (16%), hypotension (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (46%), headache (23% to 28%), insomnia (14% to 28%), rigors (22%), dizziness (18% to 21%), chills (16%), pain (5% to 13%), confusion (8% to 12%), lethargy (12%), hypoesthesia (11%), anxiety (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pallor (23%), skin rash (11% to 19%), erythema (5% to 14%), cellulitis (9% to 12%), pruritus (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (6% to 33%), hypoalbuminemia (7% to 24%), hypomagnesemia (5% to 24%), hypokalemia (12% to 22%), hyponatremia (19%), hyperkalemia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (40% to 42%), constipation (30% to 35%), diarrhea (28% to 34%), vomiting (16% to 25%), anorexia (&le;8% to 23%), decreased appetite (&le;8% to 23%), abdominal pain (5% to 14%), stomatitis (11% to 12%), dyspepsia (10% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (38% to 90%; grades 3/4: 37% to 87%; recovery 28 to 50 days), thrombocytopenia (27% to 89%; grades 3/4: 24% to 85%), anemia (31% to 82%; grades 3/4: 22%), petechia (12% to 39%), febrile neutropenia (20% to 29%; grades 3/4: 23%), leukopenia (6% to 28%; grades 3/4: 22%), bruise (9% to 22%), oral mucosal petechiae (13%), lymphadenopathy (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (6% to 14%), increased serum alkaline phosphatase (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Localized tenderness (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (17% to 20%), limb pain (18% to 19%), back pain (17% to 18%), weakness (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (27% to 40%), dyspnea (29%), pneumonia (20% to 22%), pharyngitis (16%), rales (8% to 14%), epistaxis (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (6% to 53%), lesion (5% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">5% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (8%), chest wall pain (7%), chest pain (&le;6% to 7%), chest discomfort (&le;6% to 7%), facial edema (6%), hypertension (6%), cardiac failure (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Depression (9%), falling (8%), malaise (5%), mouth pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (8%), xeroderma (8%), urticaria (6%), catheter site erythema (5%), night sweats (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperuricemia (10%), weight loss (9%), increased lactate dehydrogenase (8%), dehydration (6% to 8%), hypochloremia (6%), increased serum bicarbonate (6%), decreased serum bicarbonate (5%), hypoproteinemia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Mucosal inflammation (9%), gingival hemorrhage (8%), hemorrhoids (8%), loose stools (7%), tongue ulcer (7%), oral candidiasis (6%), toothache (6%), dysphagia (5% to 6%), abdominal distention (5%), gastroesophageal reflux disease (5%), glossalgia (5%), oral mucosa ulcer (lip: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (7%), dysuria (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hematoma (5%), pancytopenia (5%), thrombocythemia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Ascites (10%), increased serum AST (10%), decreased serum bilirubin (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Transfusion reaction (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis (10%), bacteremia (5% to 8%), staphylococcal infection (7%), tooth abscess (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Catheter infection (8%), catheter pain (5%), swelling at injection site (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (5% to 9%), muscle spasm (7%), ostealgia (6%), musculoskeletal pain (&le;6%; includes discomfort)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Polyuria (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Hypoxia (10%), upper respiratory tract infection (10%), abnormal breath sounds (5% to 10%), pharyngolaryngeal pain (8%), pulmonary edema (6%), sinusitis (5% to 6%), pleural effusion (5%), post nasal drip (5%), pulmonary signs and symptoms (crepitations: 5%), sinus congestion (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;5%, postmarketing, and/or case reports: Abscess (peridiverticular), acute cardiorespiratory failure, anaphylaxis, atrial fibrillation, cardiomyopathy, catheter site hemorrhage, cholecystitis, fungal infection, gastrointestinal hemorrhage, gingival pain, hemoptysis, hypersensitivity reaction, intracranial hemorrhage, mental status change, myocardial infarction, mycobacterium avium complex, nodule (pulmonary), pulmonary aspergillosis, pulmonary embolism, pulmonary infection (pseudomonas), pulmonary infiltrates, renal failure, sepsis, splenomegaly, supraventricular tachycardia, Sweet&rsquo;s syndrome (acute febrile neutrophilic dermatosis), urethral bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930167\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930168\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: Neutropenia and thrombocytopenia commonly occur; anemia and neutropenic fever have also been reported. Myelosuppression and worsening neutropenia are more common in first two treatment cycles and may not correlate with progression of underlying MDS. Hematologic toxicity may require dosage adjustment (after the first cycle), growth factor support, and/or antimicrobial agents. Monitor for infection. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299128\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219689\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8855&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930162\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930163\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse events were observed in animal reproduction studies. Based on the mechanism of action, decitabine may cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to use effective contraception to avoid pregnancy during treatment and for 1 month after treatment. In addition, males should be advised to avoid fathering a child while on decitabine therapy and for 2 months after treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930166\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Because of the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue breast-feeding or the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930515\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">CBC with differential and platelets (with each cycle and more frequently if needed); liver enzymes (prior to treatment initiation and periodically); serum creatinine (prior to treatment initiation and periodically)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930500\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">After phosphorylation, decitabine is incorporated into DNA and inhibits DNA methyltransferase causing hypomethylation and subsequent cell death (within the S-phase of the cell cycle). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930502\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: ~63 to 89 L/m<sup>2</sup> (Cashen 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Possibly via deamination by cytidine deaminase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~30 to 35 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322940\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Dacogen Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $2,053.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Decitabine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $1,845.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6875344\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dacogen (AR, AT, BB, BE, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, IE, IL, IN, JO, KR, LB, LK, LT, LU, MT, MY, NL, NO, PE, PH, PL, PT, RO, RU, SE, SG, SI, SK, TH, TR, UY);</li>\n      <li>Dakohen (UA);</li>\n      <li>Decbine (PH);</li>\n      <li>Xalibo (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cashen AF, Schiller GJ, O&rsquo;Donnell, MR, et al, &ldquo;Multicenter Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia,&rdquo; <i>J Clin Oncol</i>, 2010, 28(4):556-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/decitabine-drug-information/abstract-text/20026803/pubmed\" target=\"_blank\" id=\"20026803\">20026803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17564707\"></a>Cashen AF, Shah AK, Todt L, et al, &ldquo;Pharmacokinetics of Decitabine Administered as a 3-h Infusion to Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),&rdquo; <i>Cancer Chemother Pharmacol</i>, 2008, 61(5):759-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/decitabine-drug-information/abstract-text/17564707/pubmed\" target=\"_blank\" id=\"17564707\">17564707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dacogen (decitabine) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Issa JP, Garcia-Manero G, and Giles FJ, &ldquo;Phase 1 Study of Low-Dose Prolonged Exposure Schedules of the Hypomethylating Agent 5-Aza-2&rsquo;-Deoxycytidine (Decitabine) in Hematopoietic Malignancies,&rdquo; <i>Blood</i>, 2004, 103(5):1635-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/decitabine-drug-information/abstract-text/14604977/pubmed\" target=\"_blank\" id=\"14604977\">14604977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian H, Issa JP, Rosenfeld CS, et al, &ldquo;Decitabine Improves Patient Outcomes in Myelodysplastic Syndromes,&rdquo; <i>Cancer</i>, 2006, 106(8):1794-803.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/decitabine-drug-information/abstract-text/16532500/pubmed\" target=\"_blank\" id=\"16532500\">16532500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian H, Oki Y, Garcia-Manero G, et al, &ldquo;Results of a Randomized Study of 3 Schedules of Low-Dose Decitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia,&quot; <i>Blood</i>, 2007, 109(1):52-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/decitabine-drug-information/abstract-text/16882708/pubmed\" target=\"_blank\" id=\"16882708\">16882708</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22689805\"></a>Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. <i>J Clin Oncol</i>. 2012;30(21):2670-2677.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/decitabine-drug-information/abstract-text/22689805/pubmed\" target=\"_blank\" id=\"22689805\">22689805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. <i>Blood</i>. 2003;102(12):3865-3870<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/decitabine-drug-information/abstract-text/12907443/pubmed\" target=\"_blank\" id=\"12907443\">12907443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steensma DP, Baer MR, Slack JL, et al, &ldquo;Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing For Outpatient Treatment (ADOPT) Trial,&rdquo; <i>J Clin Oncol</i>, 2009, 27(23):3842-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/decitabine-drug-information/abstract-text/19528372/pubmed\" target=\"_blank\" id=\"19528372\">19528372</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. <i>JAMA</i>. 2014;312(10):1033-1048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/decitabine-drug-information/abstract-text/25203083/pubmed\" target=\"_blank\" id=\"25203083\">25203083</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8855 Version 141.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520518\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2930138\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2930507\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2930508\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15796000\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15796001\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F2930511\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2930518\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2930136\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2930512\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130971\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2930140\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725528\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401603\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2930489\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2930167\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2930168\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299128\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219689\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F2930162\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2930163\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2930166\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2930515\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2930500\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2930502\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322940\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6875344\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8855|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=decitabine-patient-drug-information\" class=\"drug drug_patient\">Decitabine: Patient drug information</a></li></ul></div></div>","javascript":null}